0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Therapeutics |

Montelukast moderately decreased asthma symptoms in children with persistent asthma

Lynnette J. Mazur, MD, MPH
[+] Article and Author Information

*See Glossary.

†Information provided by author.

P values provided by author.

Source of funding: Merck Research Laboratories.

For correspondence: Dr. B. Knorr, Respiratory & Allergy, Merck Research Laboratories, Rahway, NJ, USA.


Ann Intern Med. 2002;136(3):102. doi:10.7326/ACPJC-2002-136-3-102
Text Size: A A A

Question: In children with persistent asthma, is montelukast a well-tolerated and effective therapeutic option?

Design: Randomized {allocation concealed*}†, blinded (patients, clinicians, and {data collectors}†),* placebo-controlled trial with 12-week follow-up.

Setting: 93 centers in Africa, Australia, Europe, North America, and South America.

Patients: 689 children who were 2 to 5 years of age (mean age 4 y, 59% boys, 56% white), had ≥ 3 episodes of asthma symptoms in the previous year, had a total asthma symptom score ≥ 1 (of 24) for ≥ 8 days during the 2-week placebo baseline period, and used β-agonists for ≥ 8 days during the placebo baseline period. Exclusion criteria included asthma intubation and emergency department treatment or hospitalization for asthma within 1 month before the study. Follow-up ranged from 98% to 100% for safety and from 81% to 96% for other outcomes.

Intervention: Patients were allocated to montelukast, 4-mg chewable tablet (n = 461), or to placebo tablet (n = 228). Tablets were given once daily at bedtime for 12 weeks.

Main outcome measures: Safety, asthma symptoms, and days with β-agonist use and without asthma.

Main results: Analysis was by intention to treat for {safety}† and effectiveness end points. The montelukast and placebo groups did not differ for frequency of overall adverse effects or individual adverse effects except for asthma, which occurred more frequently in the placebo group (30% vs 38%, difference 8.0%, 95% CI 0.18 to 16). The groups did not differ for discontinuation of treatment because of adverse effects (3.5% vs 3.1% {P > 0.999}‡). Groups did not differ for ≥ 1 laboratory adverse effect (3.6% vs 5.4%, {P = 0.31}‡). Montelukast decreased asthma symptom scores (Table) and days with β-agonist use (49% vs 55%, P = 0.001) and increased days without asthma (34% vs 28%, P = 0.002) more than did placebo.

Conclusion: In children with persistent asthma, montelukast was well tolerated, decreased asthma symptom scores and β-agonist use, and increased days without asthma.

Montelukast vs placebo at 12 wk in children with persistent asthma

Outcomes§Mean decrease in score from baselineLeast-square mean difference (CI)
MontelukastPlacebo
Overall daytime asthma symptom score||0.370.260.12 (0.04 to 0.20)
Overnight asthma symptom score||0.460.370.11 (0.01 to 0.21)

§No symptoms = 0; severe symptoms = 4 or 5.

||A correction was made at this point in the table. See Notices and Corrections for details.

Topics

asthma ; montelukast

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)